Zynerba is focused on improving the lives of patients with rare neurological disorders by developing and commercializing next-generation cannabinoid therapeutics. They use transdermal delivery, which allows the drug to be absorbed through the skin directly into the bloodstream, reducing adverse effects associated with oral dosing. Their lead product candidate, Zygel, is a permeation-enhanced gel formulated with cannabidiol (CBD) for transdermal delivery. Zynerba is currently assessing Zygel in Fragile X Syndrome, 22q11.2 Deletion Syndrome, and Autism Spectrum Disorder. They are also developing two other therapeutic candidates, ZYN001 and ZYN002, for fibromyalgia, neuropathic pain, chronic cancer pain, epilepsy, and rheumatoid arthritis.